Patent intelligence · US
US 7820162
Methods for chemically synthesizing immunoglobulin chimeric proteins
Methods for chemically synthesizing immunoglobulin chimeric proteins
Patent details — US 7820162
- Jurisdiction
- US
- Status
- granted
- Grant date
- Oct 26, 2010
- Expiration
- Oct 21, 2030
- Applicant
- Syntonix Pharmaceuticals, Inc.
- Claims
- 16
- CPC classes
- A61K, A61K38/00, A61K47/60, A61K47/642
Quick answer
US 7820162 (Methods for chemically synthesizing immunoglobulin chimeric proteins) is held by Syntonix Pharmaceuticals, Inc.. Status: granted. Granted Oct 26, 2010. Expires Oct 21, 2030 (4 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Syntonix Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 16
- CPC classes
- A61K, A61K38/00, A61K47/60, A61K47/642, A61K47/68, A61K47/6811
More from Syntonix Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12383733
Iontophoresis-based patch type medicine absorption device
granted -
US 12365879
Synthetic chimeric poxviruses
granted -
US 12304901
Selective ligands for tau aggregates
granted -
US 12156897
Magnesium-containing oxytocin formulations and methods of use
granted -
US 12156864
Analogs of cyclobenzaprine and amitryptilene
granted -
US 12097183
Pharmaceutical composition for treating migraine
granted -
US 12090139
Formulations comprising triptan compounds
granted -
US 11998516
Methods and compositions for treating depression using cyclobenzaprine
granted
Frequently asked questions
What is US patent 7820162?
US 7820162 (Methods for chemically synthesizing immunoglobulin chimeric proteins) is held by Syntonix Pharmaceuticals, Inc.. Status: granted. Granted Oct 26, 2010. Expires Oct 21, 2030 (4 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7820162?
Syntonix Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 86 pharmaceutical patents for this assignee.
When does US 7820162 expire?
Our index shows an expiration date of Oct 21, 2030 (4 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.